BioMarin Pharmaceutical, Inc. (BMRN)
66.99
+0.02
(+0.03%)
USD |
NASDAQ |
Sep 03, 10:42
BioMarin Pharmaceutical Research and Development Expense (TTM) : 766.68M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 766.68M |
| March 31, 2026 | 721.03M |
| December 31, 2025 | 700.97M |
| September 30, 2025 | 682.06M |
| June 30, 2025 | 678.45M |
| March 31, 2025 | 700.93M |
| December 31, 2024 | 747.18M |
| September 30, 2024 | 779.92M |
| June 30, 2024 | 786.34M |
| March 31, 2024 | 779.91M |
| December 31, 2023 | 746.77M |
| September 30, 2023 | 713.27M |
| June 30, 2023 | 679.79M |
| March 31, 2023 | 660.62M |
| December 31, 2022 | 649.61M |
| September 30, 2022 | 637.95M |
| June 30, 2022 | 637.99M |
| March 31, 2022 | 640.90M |
| December 31, 2021 | 628.79M |
| September 30, 2021 | 624.37M |
| June 30, 2021 | 613.55M |
| March 31, 2021 | 634.58M |
| December 31, 2020 | 628.12M |
| September 30, 2020 | 644.26M |
| June 30, 2020 | 670.17M |
| Date | Value |
|---|---|
| March 31, 2020 | 673.67M |
| December 31, 2019 | 715.01M |
| September 30, 2019 | 717.58M |
| June 30, 2019 | 706.03M |
| March 31, 2019 | 695.97M |
| December 31, 2018 | 696.33M |
| September 30, 2018 | 689.55M |
| June 30, 2018 | 682.24M |
| March 31, 2018 | 649.70M |
| December 31, 2017 | 610.75M |
| September 30, 2017 | 617.39M |
| June 30, 2017 | 624.12M |
| March 31, 2017 | 648.12M |
| December 31, 2016 | 661.90M |
| September 30, 2016 | 662.78M |
| June 30, 2016 | 660.66M |
| March 31, 2016 | 651.52M |
| December 31, 2015 | 634.81M |
| September 30, 2015 | 600.76M |
| June 30, 2015 | 567.73M |
| March 31, 2015 | 518.03M |
| December 31, 2014 | 468.22M |
| September 30, 2014 | 423.47M |
| June 30, 2014 | 385.84M |
| March 31, 2014 | 363.30M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 1.509B |
| Incyte Corp. | 2.098B |
| Vertex Pharmaceuticals, Inc. | 3.907B |
| BridgeBio Pharma, Inc. | 505.38M |
| Ionis Pharmaceuticals, Inc. | 923.08M |